Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) targeted antibodies in combination with chemotherapy has improved outcomes of HER2 positive (pos) breast cancer (BC) but toxicity of therapy remains a problem. High levels of tumor-infiltrating lymphocytes are associated with increased path...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramamoorthi, Ganesan, Kodumudi, Krithika, Snyder, Colin, Grover, Payal, Zhang, Hongtao, Greene, Mark I, Basu, Amrita, Gallen, Corey, Wiener, Doris, Costa, Ricardo L B, Han, Hyo S, Koski, Gary, Czerniecki, Brian J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204433/
https://www.ncbi.nlm.nih.gov/pubmed/35710296
http://dx.doi.org/10.1136/jitc-2022-004841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204433/
https://www.ncbi.nlm.nih.gov/pubmed/35710296
http://dx.doi.org/10.1136/jitc-2022-004841

Ejemplares similares